



MEN

**FIRST CANCER SITE
RECTUM**
**RECTUM
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**RETTO
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	0	SIR	EAR	EAR
ALL SITES, BUT SKIN AND RECTUM	2378	0.83	3170	1.07	792	6.61	354	0.72	1117	0.84	584	0.85	323	0.94	-3.57	1.40
HEAD AND NECK	91	0.79	94	0.78	3	0.58	15	0.70	48	0.86	21	0.81	7	0.60	-0.18	-0.19
ORAL CAVITY	21	0.79	22	0.79	1	0.84	5	1.01	13	1.01	2	0.33	1	0.36	-0.04	-0.04
PHARYNX	22	0.94	23	0.94	1	0.94	5	1.13	11	0.96	5	0.95	1	0.44	-0.01	-0.01
LARYNX	48	0.74	49	0.72	1	0.34	5	0.41	24	0.76	14	0.96	5	0.76	-0.12	-0.13
OESOPHAGUS	28	0.93	33	1.05	5	3.75	7	1.28	11	0.76	7	1.00	3	0.90	-0.02	0.01
STOMACH	164	0.87	176	0.89	12	1.43	22	0.65	85	0.96	41	0.92	16	0.73	-0.18	-0.15
COLON RECTUM	240	0.58	632	1.47	392	22.96	42	0.60	129	0.67	36	0.36	33	0.65	-1.29	1.45
COLON	233	0.82	615	2.09	382	33.08	41	0.86	123	0.94	36	0.52	33	0.92	-0.37	2.30
RECTUM	7	0.05	17	0.13	10	1.81	1	0.04	6	0.10	0	0.00	0	0.00	-0.92	-0.85
LIVER	75	0.64	104	0.85	29	5.86	14	0.69	30	0.55	21	0.76	10	0.73	-0.31	-0.13
GALLBLADDER	23	0.70	25	0.73	2	1.46	4	0.72	7	0.46	9	1.14	3	0.72	-0.07	-0.06
PANCREAS	45	0.56	48	0.57	3	0.89	11	0.80	15	0.40	12	0.62	7	0.70	-0.27	-0.26
LUNG	466	0.90	518	0.96	52	2.33	49	0.53	225	0.92	128	1.05	64	1.07	-0.39	-0.16
SKIN MELANOMA	35	0.89	39	0.95	4	2.54	4	0.61	18	0.98	7	0.73	6	1.24	-0.03	-0.01
MESOTHELIOMA	14	0.94	15	0.97	1	1.68	4	1.61	5	0.72	4	1.11	1	0.54	-0.01	0.00
KAPOSI SARCOMA	2	0.33	3	0.47	1	3.76	0	0.00	1	0.35	1	0.70	0	0.00	-0.03	-0.02
SOFT TISSUE	9	0.90	10	0.96	1	2.38	0	0.00	4	0.86	4	1.68	1	0.82	-0.01	0.00
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	3	0.47	3	0.46	0	0.00	2	1.84	1	0.34	0	0.00	0	0.00	-0.02	-0.03
PROSTATE	441	0.75	526	0.86	85	3.63	66	0.68	199	0.73	116	0.79	60	0.81	-1.11	-0.62
TESTIS	1	0.37	2	0.70	1	7.72	1	1.87	0	0.00	0	0.00	0	0.00	-0.01	-0.01
KIDNEY AND RENAL PELVIS	108	1.20	185	1.97	77	20.68	29	1.87	50	1.18	19	0.88	10	0.94	0.13	0.65
BLADDER AND URINARY TRACT	343	1.03	423	1.22	80	5.68	49	0.85	156	1.00	85	1.06	53	1.31	0.07	0.54
URINARY BLADDER	326	1.02	402	1.21	76	5.63	48	0.87	150	1.00	80	1.05	48	1.25	0.05	0.49
URINARY TRACT	17	1.18	21	1.40	4	6.73	1	0.41	6	0.90	5	1.44	5	2.71	0.02	0.04
BRAIN AND CENTRAL NERVOUS SYSTEM	17	0.52	20	0.59	3	2.15	2	0.34	7	0.45	1	0.13	7	1.94	-0.12	-0.10
THYROID	15	1.24	17	1.35	2	3.93	3	1.40	11	1.90	1	0.35	0	0.00	0.02	0.03
HODGKIN LYMPHOMA	1	0.19	1	0.18	0	0.00	0	0.00	0	0.00	1	0.83	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	68	0.83	75	0.88	7	2.06	10	0.71	30	0.79	21	1.08	7	0.72	-0.10	-0.07
MYELOMA	21	0.53	25	0.61	4	2.40	2	0.29	8	0.44	6	0.63	5	1.03	-0.14	-0.12
LEUKAEMIAS	75	1.10	86	1.21	11	3.74	8	0.67	35	1.10	18	1.11	14	1.69	0.05	0.11
LYMPHOID LEUKAEMIAS	35	1.08	46	1.36	11	7.81	5	0.87	13	0.85	12	1.57	5	1.31	0.02	0.09
MYELOID LEUKAEMIAS	38	1.23	38	1.18	0	0.00	3	0.57	20	1.40	6	0.81	9	2.34	0.05	0.04
OTHER LEUKAEMIAS	2	0.39	2	0.37	0	0.00	0	0.00	2	0.84	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	100	0.63	127	0.77	27	4.11	11	0.41	48	0.65	25	0.66	16	0.80	-0.43	-0.27

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
RECTUM

RECTUM

POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

RETTO

POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	27053		30051		30051		27053		20815		8174		3239		27053	30051
Person-years ▶	112555		117289		4734		19701		52364		26797		13693		112555	117289
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND RECTUM	1299	0.99	1654	1.21	355	6.70	202	0.93	572	0.97	328	1.00	197	1.08	-0.16	2.42
HEAD AND NECK	13	0.76	13	0.73	0	0.00	1	0.35	10	1.30	1	0.24	1	0.43	-0.04	-0.04
ORAL CAVITY	6	0.64	6	0.61	0	0.00	0	0.00	5	1.19	0	0.00	1	0.74	-0.03	-0.03
PHARYNX	2	0.56	2	0.54	0	0.00	1	1.63	1	0.61	0	0.00	0	0.00	-0.01	-0.01
LARYNX	5	1.23	5	1.18	0	0.00	0	0.00	4	2.14	1	1.01	0	0.00	0.01	0.01
OESOPHAGUS	8	1.14	8	1.10	0	0.00	1	0.87	6	1.94	1	0.57	0	0.00	0.01	0.01
STOMACH	76	0.85	86	0.93	10	2.62	10	0.66	35	0.88	17	0.77	14	1.15	-0.12	-0.06
COLON RECTUM	125	0.57	286	1.24	161	18.13	31	0.86	51	0.52	24	0.43	19	0.60	-0.85	0.48
COLON	111	0.70	266	1.61	155	24.43	27	1.05	47	0.67	22	0.55	15	0.65	-0.43	0.86
RECTUM	14	0.23	20	0.31	6	2.37	4	0.39	4	0.14	2	0.13	4	0.47	-0.43	-0.38
LIVER	26	0.68	29	0.73	3	1.94	2	0.32	11	0.65	11	1.15	2	0.36	-0.11	-0.09
GALLBLADDER	13	0.42	16	0.49	3	2.30	1	0.19	6	0.43	1	0.13	5	1.12	-0.16	-0.14
PANCREAS	42	0.72	44	0.73	2	0.88	8	0.87	14	0.55	14	0.95	6	0.67	-0.14	-0.14
LUNG	152	1.75	164	1.82	12	3.60	16	1.16	70	1.82	45	2.05	21	1.65	0.58	0.63
SKIN MELANOMA	31	1.33	35	1.45	4	4.39	5	1.31	10	0.95	13	2.25	3	0.95	0.07	0.09
MESOTHELIOMA	3	0.85	3	0.82	0	0.00	0	0.00	3	1.93	0	0.00	0	0.00	0.00	-0.01
KAPOSI SARCOMA	1	0.51	1	0.49	0	0.00	0	0.00	0	0.00	1	2.06	0	0.00	-0.01	-0.01
SOFT TISSUE	5	0.90	6	1.04	1	4.52	2	2.19	1	0.40	2	1.45	0	0.00	0.00	0.00
BONE	1	0.66	1	0.63	0	0.00	1	3.77	0	0.00	0	0.00	0	0.00	0.00	-0.01
BREAST	353	1.08	412	1.21	59	4.47	59	1.07	158	1.05	83	1.04	53	1.25	0.23	0.61
CERVIX UTERI	20	1.19	30	1.71	10	13.43	0	0.00	11	1.39	5	1.29	4	2.11	0.03	0.11
CORPUS UTERI	86	1.44	106	1.70	20	8.19	7	0.68	33	1.19	25	1.73	21	2.80	0.23	0.37
OVARY	41	0.98	47	1.08	6	3.51	8	1.13	24	1.26	7	0.69	2	0.37	-0.01	0.03
KIDNEY AND RENAL PELVIS	42	1.27	67	1.96	25	19.74	12	2.28	20	1.36	9	1.08	1	0.21	0.08	0.28
BLADDER AND URINARY TRACT	60	1.11	77	1.37	17	7.91	10	1.14	22	0.92	13	0.95	15	1.90	0.05	0.18
URINARY BLADDER	54	1.07	71	1.36	17	8.51	10	1.23	19	0.86	11	0.87	14	1.92	0.03	0.16
URINARY TRACT	6	1.55	6	1.50	0	0.00	0	0.00	3	1.79	2	2.03	1	1.68	0.02	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	11	0.56	12	0.59	1	1.28	2	0.62	6	0.68	3	0.62	0	0.00	-0.08	-0.07
THYROID	32	1.54	34	1.57	2	2.42	4	1.13	14	1.44	7	1.40	7	2.78	0.10	0.11
HODGKIN LYMPHOMA	3	1.01	3	0.97	0	0.00	2	3.76	1	0.72	0	0.00	0	0.00	0.00	0.00
NON-HODGKIN LYMPHOMA	40	0.79	45	0.85	5	2.50	4	0.48	17	0.75	10	0.79	9	1.28	-0.10	-0.07
MYELOMA	20	0.82	20	0.78	0	0.00	4	0.99	5	0.46	5	0.82	6	1.74	-0.04	-0.05
LEUKAEMIAS	37	1.05	41	1.12	4	2.78	5	0.86	18	1.15	9	1.02	5	1.01	0.02	0.04
LYMPHOID LEUKAEMIAS	17	1.09	19	1.17	2	3.09	2	0.76	8	1.15	4	1.04	3	1.41	0.01	0.02
MYELOID LEUKAEMIAS	14	0.85	15	0.88	1	1.53	3	1.12	7	0.96	4	0.97	0	0.00	-0.02	-0.02
OTHER LEUKAEMIAS	6	1.86	7	2.08	1	7.41	0	0.00	3	2.12	1	1.23	2	4.29	0.02	0.03
OTHER AND ILL DEFINED SITES	72	0.67	88	0.79	16	3.71	11	0.63	30	0.64	24	0.89	7	0.44	-0.31	-0.20

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio